We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+35.45%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.39B
AUM Growth
+$291M
Cap. Flow
+$36.6M
Cap. Flow %
2.63%
Top 10 Hldgs %
62%
Holding
63
New
10
Increased
3
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$139M
2
GTH
Genetron Holdings Limited ADS
GTH
+$85.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.9M
4
IMVT icon
Immunovant
IMVT
+$17.1M
5
KURA icon
Kura Oncology
KURA
+$15.1M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$37.8M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$32.2M
3
ASND icon
Ascendis Pharma A/S
ASND
+$28.2M
4
LITS
Lite Strategy Inc
LITS
+$26.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.39%
2 Financials 8.49%
3 Materials 3.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
51
Aclaris Therapeutics
ACRS
$835M
$2.67M 0.19%
1,647,214
– –
MREO
52
Mereo BioPharma
MREO
$51.4M
$2.38M 0.17%
+778,000
New +$1.37M
DBVT
53
DBV Technologies
DBVT
$811M
$1.19M 0.09%
27,000
– –
DTIL icon
54
Precision BioSciences
DTIL
$188M
$1.17M 0.08%
4,675
– –
COLL icon
55
Collegium Pharmaceutical
COLL
$1.16B
– –
-447,173
Closed -$7.3M
QURE icon
56
uniQure
QURE
$3.03B
– –
-22,932
Closed -$1.09M
SLNO
57
DELISTED
Soleno Therapeutics
SLNO
– –
-134,758
Closed -$4.81M
XENE icon
58
Xenon Pharmaceuticals
XENE
$6.19B
– –
-396,589
Closed -$4.5M
KRTX
59
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-223,692
Closed -$16.1M
TRIL
60
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-2,054,468
Closed -$8.3M
CHMA
61
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-1,272,156
Closed -$4.64M
NBRV
62
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-6,817
Closed -$980K
FTSV
63
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-395,691
Closed -$37.8M
1 2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Vivo Capital held 63 positions worth $1.39B, up 26% from $1.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vivo Capital's Q2 2020 filing shows 10 new, 3 increased, 21 reduced and 9 closed positions. Its largest new stake was Legend Biotech: 3,555,007 shares worth $151M. The largest sale was Forty Seven, Inc. Common Stock, an estimated $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q2 2020 buy was Legend Biotech: 3,555,007 shares worth $151M.
  • Vivo Capital added most to Amyris Inc. in Q2 2020, an estimated $12.3M increase.
  • Vivo Capital's biggest Q2 2020 reduction was Kadmon Holdings, Inc., cutting an estimated $32.2M.
  • Vivo Capital fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $37.8M.
  • Vivo Capital's ten largest holdings make up 62% of its $1.39B portfolio in Q2 2020.
  • Vivo Capital opened 10 new positions and closed 9 in Q2 2020.
  • Vivo Capital's portfolio value rose 26% quarter-over-quarter to $1.39B.

Based on Vivo Capital's 13F filing for Q2 2020, filed 14 Aug 2020.